Connection

Denis Guttridge to Dose-Response Relationship, Drug

This is a "connection" page, showing publications Denis Guttridge has written about Dose-Response Relationship, Drug.
  1. The TLR7/8/9 Antagonist IMO-8503 Inhibits Cancer-Induced Cachexia. Cancer Res. 2018 12 01; 78(23):6680-6690.
    View in: PubMed
    Score: 0.029
  2. Oral resveratrol therapy inhibits cancer-induced skeletal muscle and cardiac atrophy in vivo. Nutr Cancer. 2011; 63(5):749-62.
    View in: PubMed
    Score: 0.017
  3. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol. 2006 Apr 20; 24(12):1852-9.
    View in: PubMed
    Score: 0.012
  4. Suppression of tumor necrosis factor-mediated apoptosis by nuclear factor kappaB-independent bone morphogenetic protein/Smad signaling. J Biol Chem. 2001 Oct 19; 276(42):39259-63.
    View in: PubMed
    Score: 0.009
  5. IkappaBalpha gene transfer is cytotoxic to squamous-cell lung cancer cells and sensitizes them to tumor necrosis factor-alpha-mediated cell death. Am J Respir Cell Mol Biol. 1999 Aug; 21(2):238-45.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.